Skip to main content
. 2020 May 5;10:555. doi: 10.3389/fonc.2020.00555

Figure 2.

Figure 2

Percentage of patients prescribed (A) alpha1 antagonists, (B) 5a-reductase inhibitors, and (C) antimuscarinic agents to treat symptoms in the months following SBRT for their prostate cancer.